Barclays lowered the firm’s price target on Idexx Laboratories (IDXX) to $481 from $570 and keeps an Overweight rating on the shares. The firm sees the softer visit trends continuing based on its interaction with vets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- IDEXX Laboratories Reports Robust Q3 2024 Performance
- Idexx Laboratories narrows 2024 EPS view to $10.37-$10.53 from $10.31-$10.59
- Idexx Laboratories reports Q3 EPS $2.80, consensus $2.68
- IDXX Upcoming Earnings Report: What to Expect?
- Idexx Laboratories price target lowered to $500 from $510 at Stifel